New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

SPMS health costs are high, and higher still for younger patients and those with severe disability, a real-world study in ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in ...

A Prescription Drug User Fee target date of September 28, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

in patients with non-relapsing secondary progressive multiple sclerosis (SPMS). The first peer-reviewed results of the Phase 3 HERCULES trial published online today in the New England Journal of ...

SAN DIEGO — Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients with non-relapsing secondary progressive multiple sclerosis ...